testing – PressAP

JCN Newswire

MHI Group Launches Phase 2 of Demonstration Testing of Automated Valet Parking System Using AGV Robots

November 18, 2022

TOKYO, Nov 18, 2022 - (JCN Newswire via SEAPRWire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) and Mitsubishi Heavy Industries Machinery Systems, Ltd. today launched Phase 2 of demonstration testing of an automated valet parking system at Shisui Premium Outlets', an outlet mall located in Chiba Prefecture. The system employs automated guided vehicle (AGV) robots, dubbed "Stan," manufactured by Stanley Robotics, a French venture-backed company.Automated valet parkingPhase 1 of the demonstration testing of this automated valet parking system, the first application of its kind in a commercial complex in Japan, took place in June 2022(1). The initial phase had two core aims: to verify handling performance using AGV robots, and to evaluate user satisfaction. For Phase 2, the original system has been upgraded with the addition of a newly developed smartphone app, and testing will focus on verifying the enhanced system's performance in automating the four aspects of valet parking: vehicle drop-off, transportation to the parking space, parking, and delivery and exiting. As in Phase 1, the demonstration testing will take place in a designated parking zone at Shisui Premium Outlets, an outlet mall in Chiba Prefecture developed and operated by Mitsubishi Estate-Simon Co., Ltd., with cooperation from Mitsubishi Estate Group. Vehicles of personnel affiliated with the mall will be used.Deployment of the enhanced automated valet parking system enables significant reduction in waiting time at vehicle pick-up, as the user can confirm the vehicle's readiness and the congestion status by smartphone app. User convenience and safety are further enhanced as the vehicle can be dropped off and picked up without human contact, reducing risk of COVID infection. For the business operator, system deployment generates new value by providing the user with extra time to enjoy shopping and dining within the commercial complex. MHI Group will apply the knowledge gained from the demonstration testing toward achieving early commercialization and adoption of automated valet parking systems at commercial complexes, airports, amusement parks, hospitals, and other large-scale facilities throughout Japan.MHI Group, as part of its growth strategy under its 2021 Medium-Term Business Plan, is currently taking steps to develop its solutions business through achievement of smart social infrastructures, in a quest to realize a carbon neutral society. This project is one of various initiatives the Company is working on to support "CASE"(2) era infrastructure building. By taking the lead in providing AGV robot-based automated valet parking systems, MHI Group will contribute to the realization of a safe, convenient and sustainable society.(1) For details:https://www.mhi.com/news/220613.html(2) "CASE" is an acronym derived from the words "connected," "autonomous," "shared" and "electric." It refers to the current technological trend in the automotive industry to create next-generation mobility services that offer outstanding safety and convenience.For more information, visit www.mhi.com/news/221118.html. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

JCN Newswire

MHI Group to Participate in Vehicle-to-Infrastructure (V2I) Demonstration Test Program to Support Autonomous Highway Driving

October 6, 2022

TOKYO, Oct 6, 2022 - (JCN Newswire via SEAPRWire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) and two Group companies -- Mitsubishi Heavy Industries Machinery Systems, Ltd. (MHI-MS) and Mitsubishi Heavy Industries Engineering, Ltd. (MHIENG) -- will participate in demonstration testing of a vehicle-to-infrastructure (V2I) system(1) to be conducted in FY2023 using a section of the Shin-Tomei Expressway (numbered E1A) currently under construction by Central Nippon Expressway Company Limited (NEXCO-Central). MHI Group will apply its diverse technologies in the test program and perform oversight of the V2I system, in preparation toward realizing tomorrow's automated driving society, especially as it relates to highway driving.Conceptual Image. Information in the forward direction undetectable by the onboard unit of an autonomous vehicle following another vehicle is transmitted to the rearward vehicle by V2I.MHI-MS was selected to take part in the demonstration testing project, which is operated by NEXCO-Central, in an open call for participants. MHI-MS applied jointly with Spectee Inc., a company that undertakes risk visualization using artificial intelligence (AI) and other state-of-the-art technologies. The demonstration testing will be carried out in a section, approximately 4 kilometers long, of E1A within Shizuoka Prefecture, part of the new expressway, not yet in service, stretching from the Shin-Hadano Interchange in Kanagawa Prefecture to the Shin-Gotemba Interchange in Shizuoka.The testing will demonstrate three core functions: 1) provision, by V2I, of information on road obstacles in the forward direction to an autonomously driven vehicle behind, whose onboard sensors are incapable of detecting such forward information; 2) provision of optimal speed information, according to the given road conditions and driving environment; and 3) provision of coupling information enabling autonomous vehicle platooning according to the destination. MHI Group will contribute to the project by providing MHI-MS's road traffic sensors and communication technologies cultivated through its experience with expressway toll collection system and road pricing system for urban zones, and MHIENG's expertise accrued from its track record in integrating safe railway systems through cooperation between wayside and onboard systems.Provision of data on forward driving conditions to a vehicle behind will enable the driver in the rear to recognize danger early and take precautionary action without excessive urgency, thereby contributing to fewer traffic accidents. Ability to follow closely behind another vehicle called platooning reduces air resistance and saves energy, and availability is enhanced by matched support via V2I communication. Even when rates of adoption of automated vehicles or connected cars with ICT unit functions are low in the context of total vehicle traffic, these V2I technologies can be used to provide real-time road traffic and safety information. They are thus expected to be of advantage to all vehicle traffic, by reducing traffic accidents and enabling more advanced road management.Today, as the shift to "CASE" vehicles(2) revolutionizes the automotive industry, the quest for improved safety, higher efficiency, and a lighter environmental footprint remains unchanged. The vision for the future of automobiles meshes perfectly with the MHI Group initiatives for sustainability. Today, as part of its 2021 Medium-Term Business Plan's growth strategy, the Company is working to develop solutions businesses in smart social infrastructure, in order to realize a carbon neutral society, and the NEXCO-Central project is one of various initiatives being taken to create infrastructure supporting the shift to CASE vehicles. Through participation in the demonstration testing program, MHI Group will input its comprehensive capabilities cultivated through its long years of building transportation infrastructure, and going forward the Company will seek to realize a society of autonomous driving enabled by advances in AI and digitalization.(1) Vehicle-to-infrastructure (V2I) systems use wireless communication to connect "connected" vehicles having ICT functions and related infrastructure components.(2) "CASE" is an acronym derived from the words "connected," "autonomous," "shared" and "electric." It refers to the current technological trend in the automotive industry to create next-generation mobility services offering outstanding safety and convenience.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

Dammam Valley/KSA to acquire the majority of Arcensus GmbH/Germany to accelerate the global implementation of Whole Genome Sequencing in genetic diagnostics and delivery of breakthrough technologies in genomic bioinformatics

September 6, 2022

ROSTOCK, Germany & DAMMAM, KSA, Sep 5, 2022 - (ACN Newswire via SEAPRWire.com) - Dammam Valley in partnership with other investment partners, announce to acquire a majority stake in Arcensus GmbH/Germany. Arcensus, founded by Dr. Arndt Rolfs, a multi-entrepreneur in biotechnology, CEO and founder of several innovative biotech companies, is a digital health and diagnostics company providing comprehensive genomic diagnostic services based on Whole Genome Sequencing.With a cross-functional, international team of geneticists, medical experts and data scientists, Arcensus, one of the world's most innovative genetic biotechnology companies, offers its knowledge and bioinformatic expertise in genomic interpretation together with cutting-edge medical and preventive health applications. The management of Arcensus is convinced that with the worldwide implementation of Whole Genome Sequencing as the first line of genomic testing, the genomic era will start quickly and will conquer the molecular medicine market in a short time.The initiative for the take-over comes from the Kingdom's aim to improve the global speed in implementing genomic testing for the early diagnosis of genetic diseases, mainly in cancer and rare genetic disorders. The financial investment led by Dammam Valley will allow Arcensus to speed up the penetration of the worldwide markets with its innovative solutions. It will be the backbone for developing a comprehensive multi-omic strategy.Dr. Abdulrahman Al-Olayan, CEO of Dammam Valley said, "This is an important step in our global healthcare strategy for KSA, as we believe that the early diagnosis and preventive testing based on real-life genomic expertise with Whole Genome Sequencing is a key ingredient to accelerate the development of, and access to, new future treatments. As a leading technology company in genomic testing, Arcensus GmbH, founded by the visionary multi-entrepreneur, Dr. Arndt Rolfs, is best positioned to provide a deep understanding of bioinformatic technologies and data analytics infrastructure needed not only for the Kingdom of Saudi Arabia but for medical research and development efforts across the globe. A key principle of this is to preserve Arcensus' autonomy. We are delighted that the founder of Arcensus, Dr. Arndt Rolfs, will continue to manage operations, sit on the board and remain a significant shareholder."Dr. Arndt Rolfs, Arcensus founder and CEO, said, "Dammam Valley will be a tremendous partner for the global expansion to us and shares our vision for building a worldwide healthcare platform in modern preventive medicine as well as early diagnostics of all genetic diseases. This important partnership will allow us to increase the investments in our modern technology and services platform, as well as our knowledge-based data extraction of the genomic data."Under the terms of the agreement, Dammam Valley along with other investors will make a double-digit million Euro payment on a fully diluted basis. The parties agree Arcensus to continue its current business model, a network of partnerships and overall objectives following the transaction's closing. The integrity of the proprietary patient data will be maintained, as will the dedicated sales, marketing, and life sciences business activities.About Dammam ValleyEstablished in 2021, Dammam Valley is a semi-government Investment company, solely owned by Imam Abdulrahman bin Faisal University, and with a raised capital of 100,000,000 SAR. It strives to be a source and destination for biotechnology innovation and healthcare in the Middle East and is the Nation's premier hub for evaluating and incubating biotech innovations. Aiming to stimulate investment, support projects, and forge quality partnerships in the fields of Health & Biotechnology, in addition to focusing on numerous other sustainable investments in various fields of interest.About ArcensusArcensus is a digital healthcare and diagnostics company that empowers people to take control of their health. The company provides the highest-standard, secure, trusted, and comprehensive diagnostic service based on Whole Genome Sequencing. Arcensus analyses the complete genetic information in human DNA and identifies the predispositions and reasons for unclear symptoms with the help of cutting-edge bioinformatic technology, including artificial intelligence. The interpretation of the genomic data suggests better treatment options and helps individuals take preventive measures to live a healthier and longer life.From our offices in New Jersey - United States, Rostock and Berlin - Germany, a cross-functional team of genetic experts, medical doctors, and data scientists works to make the most sophisticated and best genetic interpretation with medical and health prevention applications accessible to everyone. For more information, visit https://arcensus-diagnostics.com/.Important Notice and DisclaimerThis press release contains "forward-looking statements" within the meaning of the U.S. federal securities laws. Statements contained herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "continues," "expect," "estimate," "intend," "project," and similar expressions and future or conditional verbs such as "will," "would," "should," "could," "might," "can," and "may," are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Arcensus' actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates, our ability to streamline cash usage, our requirement for additional financing and our ability to continue as a going concern, or other factors.Contact information:Arcensus GmbHAhmad Malik Communication ManagerTel: +49 381 20267000 Email: Ahmad.malik@arcensus-diagnostics.com Dammam Valley Dalal AlsarawiCommunication ManagerTel: 013 333366Email: dalal.alsarawi@dammamvalley.sa www.dammamvalley.saThis press release is issued through EmailWire(TM) (www.emailwire.com) - the global newswire service that provides Press release distribution with guaranteed results. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

Strengthen technological innovation, Basecare Medical Announces 2022 Interim Results

August 29, 2022

HONG KONG, Aug 29, 2022 - (ACN Newswire via SEAPRWire.com) - Suzhou Basecare Medical Corporation Limited ("Basecare Medical" or the "Company", together with its subsidiaries, the "Group", stock code: 2170), an innovative platform of genetic testing solutions for assisted reproduction in China, officially announced the unaudited consolidated interim results for the six months ended June 30, 2022 (the "Reporting Period").During the Reporting Period, the Group recorded revenue of RMB68.6 million, a year-on-year increase of 36.7% compared to H1 2021. This increase was primarily driven by the revenue related to PGT laboratory increased by 53.4% from RMB26.6 million to RMB40.8 million, and the revenue increased from nil to RMB354,000 related to the male-focused laboratory, mainly contributable to the sales of the flow cytometer. The gross profit margin was outstanding during the Reporting Period. The gross profit of the Group increased by 36.0% to RMB30.2 million for the six months ended June 30, 2022, with a gross profit margin of 67.9% from PGT-A. Basecare Medical has transformed from a single product company to a comprehensive scenario solutions provider in the assisted reproduction industry, providing multi-scenario solutions including PGT laboratory-related solutions, male-focused laboratory-related solutions, and cryopreservation room-related solutions. Through a parallel business model consisting of both R&D and marketing, Basecare Medical has built a closed-loop business chain based on actual clinical needs, providing custom-made scenario solutions for customers, resulting in better customer satisfaction.Focus on technological innovation to satisfy the evolving needs of the assisted reproductive marketBy adhering to the "well-crafted product" concept, Basecare Medical's R&D expenses increased significantly by 99.5% year-on-year to RMB45.5 million during the Reporting Period. Basecare Medical has established a complete series of testing kits in the pipeline of genetic testing kits, which is based on next-generation sequencing (NGS) technology. Meanwhile, the PGT-A kit from Basecare Medical is China's first third-generation IVF genetic testing kit approved by the National Medical Products Administration (NMPA). The sales revenue of PGT-A kits was RMB16.4 million, with a gross profit margin of 67.9%. Meanwhile, the other two PGT products, PGT-M and PGT-SR kits are also under development. The PGT-M kit is the first and only product of its kind in China that has completed the registration test, and the PGT-SR kit is the world's first original technology to achieve effective testing of chromosomal balanced translocations through the high-throughput sequencing platform, which obtained the national invention patent technology and may become the first standardized commercial product in this series of products in China with the potential for mass clinical application. After the PGT-M and PGT-SR kits are approved for registration by the NMPA, respectively, Basecare Medical expects to further consolidate its dominant position in the third-generation IVF genetic test kit market in China, well ahead of the Company's competitors in the potential competition. Beyond test kits, Basecare Medical has developed a number of innovative devices and instruments that can improve workflow in molecular genetic laboratories using its kits, as well as the industrial chain layout of embryo cryopreservation equipment, and has provided intelligent and automated integrated solutions for clinical trials to improve the Company's competitiveness.R&D and marketing develop synergistically, the commercialization process shows a steady upward trendAlthough a significant portion of products was directly sold to hospitals and testing institutions, Basecare Medical also sold testing kits to distributors, who in turn sold the Company's products to hospitals. With an outstanding marketing team, Basecare Medical provides services to key customers such as third-generation IVF licensed hospitals and testing institutions, which are a major component of the Company's customers. The Company's marketing team is also responsible for promoting products to hospitals through academic marketing activities and interactions with KOLs and other industry professionals. At present, Basecare Medical has collaborated with over 200 medical institutions across the PRC, including 60 leading reproductive centers. With the first NMPA-approved PGT kit in China, Basecare Medical enjoys first-mover advantages in building and solidifying its sales channels and customer base. Basecare Medical plans to focus its commercialization strategy on key hospitals. The Company will increase the coverage and penetration of hospitals licensed to conduct PGT and develop stronger relationships with them to enhance customer stickiness and lay the foundation to offer other products to them in the future. Moreover, Basecare Medical plans to expand the share of wallet in these hospitals by offering comprehensive solutions, as well as offering new products for meeting other medical needs in these institutions. Occupy the full reproductive cycle and be a leading global medical technology companyTo accomplish the vision of becoming a leading global medical technology company, Basecare Medical will continue to capture and solidify PGT-A's sales channels and maintain the established customer relationships while accelerating the clinical registration process of PGT-M and PGT-SR kits, to rapidly establish a comprehensive product pipeline of the third-generation assisted reproduction to occupy the full reproductive cycle. Regarding the instrument pipeline, Basecare Medical intends to develop automated and intelligent hardware to upgrade the industry infrastructure and maintain technological leadership by leveraging the advancements of global leaders. It is expected that a peak in the approval and delivery of the Company's products and pipeline will be achieved in the coming two to three years. Basecare Medical will satisfy the evolving needs of the assisted reproductive market, further develop scenario solutions in assisted reproduction to better serve the infertile and eugenic public, and create more value for customers.About Suzhou Basecare Medical Corporation LimitedSuzhou Basecare Medical Corporation Limited is a third-generation IVF clinical solution provider in China and the first listed IVD company in the field of assisted reproduction (stock code: 2170.HK). It is committed to the product R&D and clinical application of gene technology in the field of reproductive health. Basecare Medical has been adhering to the "well-crafted product" concept, adhering to the industrialization road of independent R&D and localization substitution, and has built multi-scenario solutions for assisted reproduction covering PGT laboratories, andrology laboratories, and frozen storage rooms. The PGT-A (pre-implantation chromosome aneuploidy testing) kit, a class III medical device product independently developed by the company, has won China's first "special approval for innovative medical devices", filling the clinical gap of third-generation IVF genetic testing kits in China. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

Yunkang Group Announces First Interim Results Since Listing, Net Profit Rises 50% to RMB234 Million

August 12, 2022

HONG KONG, Aug 12, 2022 - (ACN Newswire via SEAPRWire.com) - Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its first interim results for the six months ended 30 June 2022 (the "Reporting Period") since its listing. Driven by favorable government policies promoting healthcare in China, the three business segments of the Group, including Diagnostic Outsourcing Services, Diagnostic Testing Services for Medical Institution Alliances, and Diagnostic Testing Services for Non-Medical Institutions have achieved rapid growth, with total revenue increasing by 81.9 % year-on-year to RMB1,378.7 million. Gross profit also increased by 68.6% to RMB651.1 million compared with the same period last year, and net profit rose by 50.0% to RMB234.4 million, establishing a new high within the same responding period.Business ReviewHigh-quality growth of three business segments and continuous expansion of income and service levels During the Reporting Period, revenue from diagnostic outsourcing services rose 40.8% to RMB680.4 million, as products involved in such areas as tumors, infectious diseases, and blood diseases were maintaining steady growth. The Group offers diagnostic outsourcing services to hospitals, other medical institutions and public institutions, along with dozens of independent laboratories, including central laboratories, provincial comprehensive laboratories and regional rapid response laboratories nationwide, covering all major clinical testing technology platforms (such as immunoassay, mass spectrometry, PCR, high-throughput sequencing, liquid chip, ultrastructural pathology and digital pathology remote diagnosis) with more than 2,000 testing items and growing.Diagnostic testing services for medical institution alliances mainly assists leading hospitals in establishing on-site diagnosis centers covering four main types (i.e. pathology, infectious disease, genetic disease and routine diagnostic tests). Revenue from this segment rose by 166.2% to RMB650.7 million as at the Reporting Period. The increase was primarily due to the rise in number of on-site diagnostic centers - climbing from 275 as of the end of 2021 to 350 as of 30 June 2022, as well as further improvements in service capabilities and expansion in service scope of the on-site diagnostic centers after preliminary construction and operation, resulting in rapid growth in average revenue of the unit on-site diagnostic centers. As of 30 June 2022, the semi-annual average revenue of the on-site diagnostic centers was RMB1.9 million, compared with a full-year average revenue of RMB2.2 million in 2021. Diagnostic testing services for medical institution alliances represent a crucial operating segment of the Group, accounting for an increasing proportion of the Group's total revenue, rising from 32.2% of total revenue for the six months ended 30 June 2021 to 47.2% of total revenue for the six months ended 30 June 2022.Revenue generated from the diagnostic testing services for non-medical institutions segment increased by 56.7% to RMB47.6 million, primarily due to the significant increase in demand for COVID-19 tests by individual customers and non-medical institution customers amid the ongoing COVID-19 epidemic.Industry Potential The year 2022 has witnessed continuous and strengthening support on the policy front. The 2022 Government Work Report has drawn attention to the need to continue promoting hierarchical diagnosis and treatment and enhance the order of medical treatment; expedite the building of national and provincial regional medical centers; promote the extension of quality medical resources to cities and counties; and improve the capacity of primary disease prevention and treatment, so that people can have convenient access to better healthcare services. The Outline of the Fourteenth Five-Year Plan for the National Economic and Social Development and the Long-Range Objectives Through the Year 2035 of the People's Republic of China, released in March 2022, has pointed out that deepening reform of the medical and health system should be focused. It clearly specifies that reforms, such as establishing a modern hospital management system, expanding the capacity of quality medical resources and balancing regional presence should be expedited. The Outline also clearly states that the capacity of public health services should be significantly enhanced, and the quality of medical and health services should achieve continuous improvement by 2025. Furthermore, the capacity of primary medical and health services should be continuously improved, the comprehensive and full-cycle health services system should be gradually enhanced, and the landscape for hierarchical diagnosis and treatment should be gradually established.With a series of supportive policies and an array of subsequent national policies for promoting a stable economy set to successively come into effect, the healthcare service market in China will possess tremendous growth potential. According to a Frost & Sullivan Report, the total healthcare service market in China is expected to reach RMB7,519.6 billion by 2025, which represents a CAGR of 9.1% from 2020 to 2025. Benefiting from the introduction of supportive policies, and growing awareness of healthcare among the population, the size of the diagnostic testing services for medical institution alliances market in China is expected to grow to RMB5,903.4 million in 2025, from RMB2,200.9 million in 2020, representing a CAGR of 21.8%, hence will present tremendous business opportunities to the Group.Development StrategyContinue to expand and strengthen medical institution alliance networkOver the next few years, the Group will primarily focus on pathology, genetic and infectious disease laboratories for medical institution alliances and further improve their precision medicine capability, expanding and strengthening its medical institution alliance network. As at 30 June 2022, there were a total of 350 on-site diagnostic centers in hospitals. At the same time, the Group currently has nearly 90 ongoing projects involving on-site diagnostic centers with hospitals that have yet to commence operation. For certain hospitals that do not currently have diagnostic capacities, the Group intends to help them improve, manage, and operate such laboratories.The Group also plans to establish more sales and customer service representative offices to enable its sales and marketing and after-sales customer service personnel to more closely interact with customers and develop stronger and deeper business relationships. This would also facilitate better understanding of customers' needs and design and provide solutions to meet such needs, which in turn enable the Group to maintain its market position.Expand portfolio of diagnostic capabilitiesThe Group plans to expand its portfolio of diagnostic capabilities, in particular, for tumors, genetic diseases, infectious diseases and pharmacogenetics, hence, it will seek to further enhance its diagnostic testing technologies, upgrade its equipment and recruit more personnel as appropriate to support the expansion. As the Group expands its diagnostic capabilities, it also plans to market its services to more non-medical institution customers, such as corporations and government agencies, so as to enhance its ability to provide omni-scenario medical operation services for customers.The Group believes that precision medicine will be a growing trend in the healthcare industry as more and more patients seek customized medical solutions. Diagnostic testing is crucial to enhance precision medicine as accurate diagnostic testing will enable physicians to understand the characteristics of the patients to customize their treatment plan. Through continued expansion of its capabilities, the Group endeavors to work with hospitals to provide precision medicine solutions to patients.Continue to upgrade and enhance operational capabilitiesThe Group plans to strategically develop small-scale self-operated independent clinical laboratories (ICLs) in selected regions and areas of China, either near the Group's major customers or based on market needs, with the aim of digitalizing diagnostic testing and developing technical and operating systems to support its operations. In order to further enhance operational capabilities, the Group may consider acquiring or investing in companies that have synergistic businesses with it, such as upstream companies engaged in advanced diagnostic techniques, molecular biology, biotechnology and their clinical applications.Yunkang Group Limited (Stock Code: 2325)Yunkang Group is a leading medical operation service provider in China, which started to provide standardized medical diagnostic services to medical institutions at all levels as early as 2008. Leveraging its own professional diagnostic capabilities and the nationwide service network of integrated healthcare systems, Yunkang has gradually grown to become a medical operation service platform. Meanwhile, Yunkang is a medical operation service provider in China offering a full suite of diagnostic testing services which are diagnostic outsourcing services and diagnostic testing services for medical institution alliances. Yunkang provides diagnostic services through on-site diagnostic centers to collaborative hospitals in the integrated healthcare systems in China, and assists them in improving their clinical diagnosis capabilities through co-developing diagnostic centers. So far, Yunkang has successfully provided professional services to 350 medical institution alliances. As of June 30, 2022, the hospitals we collaborated with were located across 31 provinces and municipalities in China. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

QualityKiosk and BrowserStack Announce Partnership Extension to the US, EMEA and APAC

July 5, 2022

MUMBAI, INDIA, Jul 5, 2022 - (ACN Newswire via SEAPRWire.com) - QualityKiosk Technologies, one of the largest independent global quality assurance service providers, announced that it is extending its partnership with BrowserStack, a leading cloud-based testing platform enabling on-demand, cross-browser and cross-device testing, into the international regions of US, EMEA and APAC. QualityKiosk's strong domain experience in quality assurance and performance engineering combined with the BrowserStack platform will enable enterprises in the region to create and deploy quality and bug-free software at pace and scale.Speaking on occasion, Mr Maneesh Jhawar, CEO & Founder, QualityKiosk Technologies, said, "QualityKiosk's QA solutions and services, coupled with the BrowserStack platform, provides enterprises with an end-to-end DevOps synergy to optimize the development, management, and up-gradation of all aspects of their business application. The partnership extension is a natural progression to helping businesses scale their digital transformation and evolution in the regions. We are excited for this new growth phase and look forward to working with BrowserStack to bring more innovative solutions and strategies for the region's expanding digital ecosystem.""We're excited to take our partnership with QualityKiosk to the next step. BrowserStack and QualityKiosk share a common objective of empowering organizations to be more agile in their DevOps practices and support them throughout the SDLC process," said Sunil Jose, EVP, Global Sales, BrowserStack. "Expanding to APAC and the US allows us to help businesses scale their testing and quality assurance needs with our partnership's dual expertise."The QualityKiosk-BrowserStack synergy has already enabled numerous businesses in the Indian subcontinent to automate, streamline, and optimize quality assurance to sustainably accelerate digital innovation, enhance end-user experiences, reduce go-to-market times and integrate agility into their development cycles. Their illustrious clientele includes some of the biggest enterprises from the banking, financial services, manufacturing, automotive, telecom, entertainment, and pharmaceutical industries.About QualityKioskQualityKiosk Technologies is a global Quality Assurance (QA) solutions provider and caters to some of the biggest names in the banking and financial services, telecom, and automobile industries across the globe. Founded in 2000 by IIT-Kanpur graduates, the company is a pioneer in digital performance engineering and offers a diverse set of quality assurance solutions including QA automation, performance assurance, Robotic Process Automation (RPA), synthetic monitoring, site reliability engineering (SRE), digital testing as a service (DTaaS), and data analytics solutions for an array of industries and verticals. In the past, the company has been featured in various industry-leading reports by prestigious global advisory firms Forrester and Everest Group. Visit https://www.qualitykiosk.com/ to know more about innovative quality assurance and performance engineering solutions.About BrowserStackBrowserStack is the world's leading software testing platform powering over two million tests every day across 15 global data centers. BrowserStack helps Tesco, Shell, NVIDIA, Discovery, Wells Fargo, and over 50,000 customers deliver quality software at speed by moving testing to their Cloud. BrowserStack's platform provides instant access to 3,000+ real mobile devices and browsers on a highly reliable cloud infrastructure that effortlessly scales as testing needs grow. With BrowserStack, Dev and QA teams can move fast while delivering an amazing experience for every customer. Founded in 2011, BrowserStack is a privately held company backed by Accel, Bond, and Insight Partners. For more information, visit https://www.browserstack.com.For more information, please contact:Naeem Shaikh+91 9819543757naeem.shaikh@qualitykiosk.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

JCN Newswire

MHI Group to Begin Demonstration Testing of Automated Valet Parking System Using AGV Robots at Outlet Mall in Chiba

June 13, 2022

TOKYO, Jun 13, 2022 - (JCN Newswire via SEAPRWire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) and Mitsubishi Heavy Industries Machinery Systems, Ltd. today launched demonstration testing of an automated valet parking system at a large-scale commercial facility near Tokyo. The system employs automated guided vehicle (AGV) robots, dubbed "Stan," manufactured by Stanley Robotics, a French venture-backed company. The event marks the first application of this type of autonomous vehicle handling system in a commercial complex in Japan.Automated valet parkingImage of demonstration testing areaStanley Robotics' AGV robot "Stan"The demonstration testing will be performed with cooperation from Mitsubishi Estate Group. It will take place in a designated parking zone at Shisui Premium Outlets', an outlet mall located in Chiba Prefecture which is operated by Mitsubishi Estate.Simon Co., Ltd. Vehicles will be transported autonomously by AGV robots in an environment close to actual application, to verify handling performance and evaluate user satisfaction.MHI Group is targeting nationwide deployment of automated valet parking systems as well as automated systems for transporting finished vehicles. Working in collaboration with Stanley Robotics, a world leader in the development and deployment of automated valet parking systems using AGV robots, MHI Group has been undertaking demonstration testing at MHI facility since October 2021. Now, with the data to be acquired through demonstration testing at a real commercial complex, MHI Group will further accelerate its initiatives toward achieving these services' commercial viability in Japan.MHI Group, as part of its growth strategy under its 2021 Medium-Term Business Plan, is currently taking steps to develop its solutions business through achievement of smart social infrastructures, in a quest to realize a carbon neutral society. This project is one of various initiatives MHI Group is working on to support "CASE"* era infrastructure. By taking the lead in providing AGV robot-based automated valet parking services at shopping malls, commercial complexes, amusement parks, airports, etc., MHI Group will contribute to the realization of a safe, comfortable and sustainable society.*"CASE" is an acronym derived from the words "connected," "autonomous," "shared" and "electric." It refers to the current technological trend in the automotive industry to create next-generation mobility services that offer outstanding safety and convenience.Concepts behind AGV robot-based automated valet parking1. Arrival: The customer parks in one of the "berths" installed next to the facility, and simply drop off the vehicle. There is no need to search for a parking space or to walk from a distant parking space even in inclement weather.2. Automated transportation: The AGV robot automatically transports the vehicle to a designated parking space. Robot-assisted parking enables more efficient use of limited space, to increase parking capacity. Storing the vehicle in the segregated parking area also prevents accidents or thefts.3. Reservation for departure: The customer can simply make a reservation for departure at any time by smartphone app. As the reservation time approaches, the vehicle is automatically transported to the berth. Since the customer can confirm the vehicle status by app, it is possible to continue shopping, dining, etc. thus making more effective use of time.4. Departure: The vehicle is available for pick-up at the berth at the reserved time, so there is no waiting. The berth is spacious, enabling easy loading of passengers and packages comfortably without stress.Automated valet parking demonstration test profile:Location: Shisui Premium Outlets' parking zone P9Schedule: June 13 (Mon) through July 1 (Fri), 2022 (subject to change)How Stanley Robotics' AGV robot "Stan" operatesThe AGV robot "Stan" equips with a platform that lifts the vehicle's 4 wheels, and automatically transports the vehicle indoors or outdoors. This robot has started commercial operation from 2018 in a parking garage at Lyon-Saint Exupery Airport in France, and has subsequently gone into service at Gatwick Airport in London.About Stanley RoboticsStanley Robotics is a deep tech company that combines hardware and software to provide solutions for outdoor logistics. The technology lies in a robot lifting and moving cars autonomously and in an intelligent storage management software. Robotics has transformed indoor logistics (e.g. in warehouses), resulting in a spectacular increase of productivity. Stanley Robotics' ambition is to bring this transformation to outdoor logistics with its proprietary technologies.Founded in 2015, the SME is headquartered in Paris, France, and is also behind the world's first outdoor robotic valet parking service. For more information, visit https://stanley-robotics.com/en/About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)